237 related articles for article (PubMed ID: 24614178)
1. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Chow PK; Poon DY; Khin MW; Singh H; Han HS; Goh AS; Choo SP; Lai HK; Lo RH; Tay KH; Lim TG; Gandhi M; Tan SB; Soo KC;
PLoS One; 2014; 9(3):e90909. PubMed ID: 24614178
[TBL] [Abstract][Full Text] [Related]
2. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
4. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
6. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
[TBL] [Abstract][Full Text] [Related]
7. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
11. A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
Suzuki E; Kaneko S; Okusaka T; Ikeda M; Yamaguchi K; Sugimoto R; Aramaki T; Asagi A; Yasui K; Sano K; Hosokawa A; Kato N; Ishii H; Sato T; Furuse J
Jpn J Clin Oncol; 2018 Apr; 48(4):317-321. PubMed ID: 29474553
[TBL] [Abstract][Full Text] [Related]
12. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
13. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
14. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
15. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
16. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
[TBL] [Abstract][Full Text] [Related]
18. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
[TBL] [Abstract][Full Text] [Related]
20. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
Merchante N; Ibarra S; Revollo B; Rodríguez-Arrondo F; Merino E; Delgado-Fernández M; Montero-Alonso M; Téllez F; Galindo MJ; Rivero-Juárez A; García MA; Mínguez C; Romero-Palacios A; Garcia-Deltoro M; Pineda JA;
AIDS; 2017 Jan; 31(1):89-95. PubMed ID: 27755109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
